Outlook Therapeutics, Inc. Common Stock (OTLK)

Price$0.78

Value ScoreD

Growth ScoreF

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-64.53%

Price vs S&P 500 (4W)250.98%

VGM Score31.72

Market Capitalization$93.87M

All Metrics

Book Value / Share (Quarterly)$0.82

P/TBV (Annual)13.70x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-22.93%

Cash Flow / Share (Quarterly)$-0.45

Price vs S&P 500 (YTD)-59.00%

Net Profit Margin (TTM)-1506.99%

EPS (TTM)$-1.26

10-Day Avg Trading Volume67.77M

EPS Excl Extra (TTM)$-1.26

Revenue Growth (5Y)-13.86%

EPS (Annual)$-1.79

ROI (Annual)-335.84%

Gross Margin (Annual)4.05%

Net Profit Margin (5Y Avg)-1724.56%

Cash / Share (Quarterly)$0.07

ROA (Last FY)-259.89%

EBITD / Share (TTM)$-1.06

Operating Margin (TTM)-1806.15%

Cash Flow / Share (Annual)$-2.87

P/B Ratio8.95x

P/B Ratio (Quarterly)26.67x

Net Income / Employee (Annual)$-3,672,100

EV / Revenue (TTM)69.27x

Net Interest Coverage (TTM)-190.32x

ROA (TTM)-300.62%

EV / EBITDA (TTM)2.79x

EPS Incl Extra (Annual)$-1.79

Current Ratio (Annual)0.63x

Quick Ratio (Quarterly)0.27x

3-Month Avg Trading Volume10.70M

52-Week Price Return-58.47%

Revenue / Employee (TTM)$25,000

Tangible BV / Share (Quarterly)$-0.02

P/S Ratio (Annual)66.41x

Asset Turnover (Annual)0.48x

52-Week High$3.39

Operating Margin (5Y Avg)-1772.52%

EPS Excl Extra (Annual)$-1.79

26-Week Price Return-56.61%

Quick Ratio (Annual)0.35x

13-Week Price Return79.87%

Total Debt / Equity (Annual)1.25x

Current Ratio (Quarterly)0.54x

Enterprise Value$113.10M

Revenue / Share Growth (5Y)-72.88%

Asset Turnover (TTM)0.07x

Revenue / Employee (Annual)$83,100

Pretax Margin (Annual)-4525.99%

Cash / Share (Annual)$0.63

3-Month Return Std Dev189.25%

Net Income / Employee (TTM)$-3,585,700

ROE (Last FY)-756.01%

Net Interest Coverage (Annual)-164.02x

EPS Basic Excl Extra (Annual)$-1.79

Total Debt / Equity (Quarterly)3.04x

EPS Incl Extra (TTM)$-1.26

ROI (TTM)-163.27%

P/S Ratio (TTM)220.92x

Pretax Margin (5Y Avg)-1775.19%

Revenue / Share (Annual)$0.04

Tangible BV / Share (Annual)$0.04

Price vs S&P 500 (52W)-82.83%

Year-to-Date Return-50.84%

5-Day Price Return-7.86%

EPS Normalized (Annual)$-1.79

ROA (5Y Avg)-217.13%

Net Profit Margin (Annual)-4416.21%

Month-to-Date Return6.40%

Cash Flow / Share (TTM)$-0.25

EBITD / Share (Annual)$-1.92

Operating Margin (Annual)-4744.24%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-2965.91%

LT Debt / Equity (Quarterly)2.02x

EPS Basic Excl Extra (TTM)$-1.26

P/B Ratio (Annual)31.58x

Inventory Turnover (TTM)0.44x

Pretax Margin (TTM)-1506.99%

Book Value / Share (Annual)$0.77

Price vs S&P 500 (13W)71.62%

Beta0.96x

Revenue / Share (TTM)$0.01

ROE (TTM)-415.51%

52-Week Low$0.16

vGradeD

gGradeF

mGradeC

vgmGradeD

Show chart for

Earnings Surprise History

Q2 26-0.16est. -0.12

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

3.90

4.00

Industry Peers — Biological Products(178)

Symbol	Value Score	Growth Score	Momentum Score	Price
OTLKOutlook Therapeutics, Inc. Common Stock	D	F	C	$0.78
AMGNAmgen Inc	C	C	C	$349.58
GILDGilead Sciences Inc	C	B	C	$129.16
ARGXargenx SE American Depositary Shares	D	A	B	$891.32
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$149.23
BIIBBiogen Inc. Common Stock	B	D	B	$195.34
BNTXBioNTech SE American Depositary Share	C	C	D	$88.08
MRNAModerna, Inc. Common Stock	C	B	B	$47.44
NBIXNeurocrine Biosciences Inc	C	B	B	$163.88
EXELExelixis Inc	C	B	B	$52.70
KRYSKrystal Biotech, Inc. Common Stock	D	B	A	$301.00

About

Outlook Therapeutics develops ONS-5010/LYTENAVA (bevacizumab-gamma), a monoclonal antibody for ophthalmic diseases. LYTENAVA has received marketing approval in the European Union and United Kingdom for wet age-related macular degeneration treatment. The company is pursuing additional indications for its lead therapy as a first-line anti-VEGF option.